ABCB1 and cancer: Wu et al.’s work has somewhat demonstrated that, as a result of inhibiting ABCB1 and ABCG2, samotolisib can be restored the efficacy in ABCB1- and ABCG2-overexpressing multidrug-resistant cancer cells.